CSF-1 Overexpression Predicts Poor Prognosis in Upper Tract Urothelial Carcinomas

Background: Colony-stimulating factor-1 (CSF-1) is a homodimeric glycoprotein. The main role of CSF-1 is as a hematopoietic growth factor that modulates proliferation, differentiation, and survival of macrophages. Moreover, CSF-1 has also been reported to be aberrantly expressed in several human cancers. However, the precise role of CSF-1 in upper tract urothelial carcinomas (UTUC) has not been studied. In this research, we examined the clinical significance of CSF-1 expression in UTUC.

Materials And Methods: One hundred twelve cancer tissue samples of UTUC from patients were included in this study, and the other cohort of 35 UTUC were paired cancer-adjacent normal samples. CSF-1 expression was evaluated by immunohistochemistry, and the association of CSF-1 expression with different clinicopathological variables was analyzed.

Results: CSF-1 expression was higher in UTUC than in the normal urothelium ( = 0.005). The CSF-1 expression was primarily localized in the nucleus and was significantly correlated with tumor size ( = 0.04) and patients who had a high stage ( < 0.001), distant metastasis ( = 0.006), recurrence ( = 0.003), and cancer death ( = 0.005). High CSF-1 expression was correlated with poor disease-free survival ( = 0.008) and cancer-specific survival ( = 0.001). Our results also used univariate and multivariable analyses, which found that high CSF-1 expression was an independent predictor of poor disease-free survival (hazard ratio = 2.56; = 0.007) and cancer-specific survival (hazard ratio = 5.14; = 0.022).

Conclusions: Our findings indicate that the expression of CSF-1 is a potential prognostic marker for predicting patient survival and recurrence in UTUC.